• LAST PRICE
    19.9500
  • TODAY'S CHANGE (%)
    Trending Down-0.1700 (-0.8449%)
  • Bid / Lots
    19.9500/ 2
  • Ask / Lots
    19.9600/ 2
  • Open / Previous Close
    19.9500 / 20.1200
  • Day Range
    Low 19.8600
    High 20.5300
  • 52 Week Range
    Low 15.3700
    High 27.8600
  • Volume
    174,925
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 20.12
TimeVolumeCRNX
09:32 ET113019.95
09:37 ET10019.995
09:39 ET10020.195
09:48 ET40020.255
09:50 ET70020.22
09:51 ET127020
09:53 ET297820.01
09:55 ET250020.075
10:00 ET140020.01
10:02 ET50020
10:06 ET20020
10:08 ET10020
10:09 ET60019.9
10:11 ET30020.01
10:13 ET90020
10:15 ET112619.935
10:20 ET20020
10:22 ET40019.95
10:24 ET10019.955
10:27 ET10019.92
10:36 ET10019.95
10:38 ET2545220.17
10:40 ET10020.225
10:42 ET1481520.255
10:44 ET20020.3099
10:47 ET50020.41
10:51 ET70020.36
10:56 ET20020.34
10:58 ET79020.2
11:02 ET10020.15
11:03 ET10020.175
11:12 ET10020.14
11:14 ET23820.16
11:18 ET10020.16
11:21 ET10020.175
11:23 ET10020.21
11:25 ET32720.235
11:27 ET30020.3
11:32 ET10020.31
11:36 ET10020.42
11:41 ET10020.36
11:45 ET150020.47
11:48 ET120220.485
11:50 ET10020.53
11:52 ET317720.25
11:54 ET10020.2
11:56 ET38820.2
11:57 ET33620.14
11:59 ET10020.08
12:03 ET30020.06
12:08 ET40020.11
12:12 ET10020.21
12:14 ET10020.12
12:19 ET10020.115
12:24 ET618219.99
12:28 ET20019.99
12:30 ET150020.05
12:32 ET11720.08
12:33 ET10020.12
12:37 ET18020.085
12:39 ET10020.11
12:42 ET10020.07
12:44 ET10020.06
12:48 ET20020.09
12:50 ET60020.11
12:51 ET10020.11
12:55 ET10020.17
01:00 ET173520.065
01:02 ET10020.1
01:04 ET10020.06
01:11 ET217619.98
01:13 ET20020
01:15 ET40019.99
01:18 ET20019.995
01:20 ET420120.0466
01:27 ET2020020.02
01:29 ET22320.05
01:31 ET50020.06
01:33 ET10020.06
01:36 ET22520.14
01:38 ET10020.14
01:40 ET60020.11
01:42 ET101020.1
01:44 ET10020.08
01:51 ET20020.1
01:54 ET50020.065
01:56 ET30020
01:58 ET20020.02
02:00 ET10020
02:02 ET87320.01
02:16 ET40020.03
02:18 ET10020.01
02:20 ET94820.03
02:21 ET20020.05
02:23 ET10020.11
02:30 ET110020.1096
02:32 ET40020.1
02:34 ET70020.075
02:36 ET160020.05
02:38 ET40020.04
02:41 ET30020
02:43 ET50019.995
02:48 ET72820
02:50 ET20020.015
02:52 ET40019.985
02:56 ET10019.985
02:57 ET20020
02:59 ET70019.97
03:01 ET20019.955
03:03 ET20019.89
03:10 ET20019.96
03:12 ET10019.965
03:14 ET31620
03:15 ET10019.97
03:24 ET130019.97
03:26 ET30020
03:28 ET59519.97
03:30 ET100019.935
03:32 ET10019.95
03:33 ET10019.96
03:37 ET40019.945
03:39 ET150019.92
03:42 ET10019.92
03:46 ET50219.95
03:48 ET60019.935
03:50 ET114119.93
03:51 ET140620.005
03:53 ET236019.95
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCRNX
Crinetics Pharmaceuticals Inc
1.1B
-6.7x
---
United StatesCOGT
Cogent Biosciences Inc
1.1B
-6.1x
---
United StatesIGMS
IGM Biosciences Inc
1.1B
-4.2x
---
United StatesINBX
Inhibrx Inc
1.1B
-8.0x
---
United StatesNAMS
NewAmsterdam Pharma Company NV
1.0B
-61.3x
---
United StatesARQT
Arcutis Biotherapeutics Inc
996.2M
-2.8x
---
As of 2023-02-03

Company Information

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. It has discovered a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) to treat a rare endocrine disease. Its product candidates include paltusotine, CRN04777 and CRN04894. Its paltusotine is in clinical development for the treatment of acromegaly and neuroendocrine tumors. CRN04777 is an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5), agonist designed for the treatment of congenital hyperinsulinism (HI). CRN04894 is an investigational, oral, nonpeptide product candidate designed for the treatment of diseases caused by excess adrenocorticotrophic hormone (ACTH), including Cushings disease, congenital adrenal hyperplasia (CAH), and Ectopic ACTH Syndrome (EAS).

Contact Information

Headquarters
10222 Barnes Canyon Rd Bldg 2SAN DIEGO, CA, United States 92121-2711
Phone
858-450-6464
Fax
302-636-5454

Executives

Independent Chairman of the Board
Wendell Wierenga
President, Chief Executive Officer, Co-Founder, Director
R. Scott Struthers
Co-Founder, Chief Scientific Officer
Stephen Betz
Chief Financial Officer
Marc Wilson
Chief Operating Officer
Jeff Knight

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.1B
Revenue (TTM)
$5.1M
Shares Outstanding
53.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.98
EPS
$-2.99
Book Value
$6.97
P/E Ratio
-6.7x
Price/Sales (TTM)
212.0
Price/Cash Flow (TTM)
---
Operating Margin
-2,961.50%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.